<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>Lipids in Health and Disease - Latest articles</title>
		<link>http://www.lipidworld.com</link>
		<description>The latest articles from Lipids in Health and Disease (ISSN 1476-511X) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.lipidworld.com/content/7/1/29"/>			    
            
				    <rdf:li rdf:resource="http://www.lipidworld.com/content/7/1/28"/>			    
            
				    <rdf:li rdf:resource="http://www.lipidworld.com/content/7/1/27"/>			    
            
				    <rdf:li rdf:resource="http://www.lipidworld.com/content/7/1/26"/>			    
            
				    <rdf:li rdf:resource="http://www.lipidworld.com/content/7/1/25"/>			    
            
				    <rdf:li rdf:resource="http://www.lipidworld.com/content/7/1/24"/>			    
            
				    <rdf:li rdf:resource="http://www.lipidworld.com/content/7/1/23"/>			    
            
				    <rdf:li rdf:resource="http://www.lipidworld.com/content/7/1/22"/>			    
            
				    <rdf:li rdf:resource="http://www.lipidworld.com/content/7/1/21"/>			    
            
				    <rdf:li rdf:resource="http://www.lipidworld.com/content/7/1/20"/>			    
            
            </rdf:Seq>
        </items>
    </channel>  
    
		<item rdf:about="http://www.lipidworld.com/content/7/1/29">
            
            <title>Isoforms of retinol-binding protein 4 (RBP4) are increased in chronic diseases of the kidney but not of the liver</title>
			<description>Background:
The levels of retinol-binding protein 4 (RBP4) - the carrier for Vitamin A in plasma - are tightly regulated under healthy circumstances. The kidney, the main site of RBP4 catabolism, contributes to an elevation of RBP4 levels during chronic kidney disease (CKD) whereas during chronic liver disease (CLD) RBP4 levels decrease. Little is known about RBP4 isoforms including apo-RBP4, holo-RBP4 as well as RBP4 truncated at the C-terminus (RBP4-L and RBP4-LL) except that RBP4 isoforms have been reported to be increased in hemodialysis patients. Since it is not known whether CLD influence RBP4 isoforms, we investigated RBP4 levels, apo- and holo-RBP4 as well as RBP4-L and RBP4-LL in plasma of 36 patients suffering from CKD, in 55 patients suffering from various CLD and in 50 control subjects. RBP4 was determined by ELISA and apo- and holo-RBP4 by native polyacrylamide gel electrophoresis (PAGE). RBP4-L and RBP4-LL were analyzed after immunoprecipitation by mass spectrometry (MALDI-TOF-MS). 
Results:
RBP4 isoforms and levels were highly increased in CKD patients compared to controls (P&lt;0.05) whereas in CLD patients RBP4 isoforms were not different from controls. In addition, during hepatic dysfunction RBP4 levels were decreased whereas the amount of isoforms was not affected. 
Conclusions:
The occurrence of RBP4 isoforms is not influenced by liver function but seems to be strongly related to kidney function and may therefore be important in investigating kidney function and related disorders.</description>
			<link>http://www.lipidworld.com/content/7/1/29</link>
			
			 	<dc:creator>Simone K. Frey, Britta Nagl, Andrea Henze, Jens Raila, Beate Schlosser, Thomas Berg, Martin Tepel, Walter Zidek, Martin O. Weickert, Andreas F. H. Pfeiffer and Florian J. Schweigert</dc:creator>
			
			<dc:source>Lipids in Health and Disease 2008, 7:29</dc:source>
			<dc:date>2008-08-27</dc:date>
			<dc:identifier>doi:10.1186/1476-511X-7-29</dc:identifier>
			
			
							
					<prism:publicationName>Lipids in Health and Disease</prism:publicationName>
					
			
							
					<prism:issn>1476-511X</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>29</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-27</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.lipidworld.com/content/7/1/28">
            
            <title>Albuminuria and its correlates in an Iranian type 2 diabetic population</title>
			<description>ObjectiveTo study the prevalence and correlates of increased urinary albumin excretion (UAE) in an Iranian type 2 diabetic population.
Methods:
Over a one year period since October 2002, 400 consecutive type 2 diabetic patients referred to an outpatient diabetes clinic, were enrolled in a cross sectional study. Subjects had no history of renal impairment or overt proteinuria. Data concerning demographic characteristics and cardiovascular risk factors were recorded and height, weight and blood pressure were measured. Glucose, cholesterol, HDL-C, LDL-C, triglyceride, apoprotein B, lipoprotein a, creatinine, and HbA1c were measured in fasting blood samples. Overnight twelve-hour UAE were assessed by immunoturbidometry method. Regression analyses were employed to determine the correlates of UAE.
Results:
Out of 400 patients, 156 (40%) subjects had increased UAE (UAE [greater than or equal to]30mg/24hour). The UAE was higher in males compared to females (145.5 vs. 72.1 mg/day; p&lt;0.05); however, the age and HDL adjusted UAE levels were not significantly different between men and women (120.1 vs. and 87.9 mg/day; p=0.37).  Increased UAE was correlated with decreasing HDL-C and a longer duration of diabetes independent of other variables; increased UAE was correlated with HbA1c as well. Age, systolic and diastolic blood pressure, total cholesterol, LDL-C, triglyceride, apoprotein B, lipoprotein a, and GFR did not correlate with increased UAE.
Conclusions:
In this study, increased UAE was considerably frequent among type 2 diabetic patients without any significant history of renal dysfunction. Albuminuria was found to be associated with dyslipidemia (low HDL-C), long duration of diabetes, and uncontrolled glycemia revealed by higher HbA1c.</description>
			<link>http://www.lipidworld.com/content/7/1/28</link>
			
			 	<dc:creator>Manouchehr Nakhjavani, Alireza Esteghamati, Fatemeh Esfahanian, Naser Aghamohammadzadeh, Sepehr Hamidi, Alipasha Meysamie and Mehrshad Abbasi</dc:creator>
			
			<dc:source>Lipids in Health and Disease 2008, 7:28</dc:source>
			<dc:date>2008-08-10</dc:date>
			<dc:identifier>doi:10.1186/1476-511X-7-28</dc:identifier>
			
			
							
					<prism:publicationName>Lipids in Health and Disease</prism:publicationName>
					
			
							
					<prism:issn>1476-511X</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>28</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-10</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.lipidworld.com/content/7/1/27">
            
            <title>The prevention of endothelial dysfunction through endothelial cell apoptosis inhibition in a hypercholesterolemic rabbit model: the effect of L-arginine supplementation  </title>
			<description>Background:
The impact of L-arginine on atherogenesis and its ability to prevent endothelial dysfunction have been studied extensively during the past years. L-arginine is a substance for nitric oxide synthesis which involves in apoptosis. Hypercholesterolemia promotes endothelial dysfunction, and it is hypothesized that L-arginine prevents endothelial dysfunction through endothelial cells apoptosis inhibition. To test this hypothesis, thirty rabbits were assigned into two groups. The control group received 1% cholesterol diet for 4 weeks, and the L-arginine group received same diets plus 3% L-arginine in drinking water.
Results:
No significant differences were observed in cholesterol level between two groups, but the nitrite concentration in L-arginine group was significantly higher than other group (control group: 11.8+/-1; L-arginine group: 14.7+/-0.5 umol/l ); (p&lt;0.05). The aorta score of fatty streak in control group was 0.875+/-0.35, but no fatty streak lesion was detected in L-arginine group (p&lt;0.05). The number of intimal apoptotic cells/500 cells of aorta in two groups of experiment were statistically different (control group: 39.3 +/- 7.6; L-arginine group: 21.5 +/- 5.3 ) (p&lt;0.05). 
Conclusion:
The inhibition of endothelial cells apoptosis by L-arginine restores endothelial function in a model of hypercholesterolemia.</description>
			<link>http://www.lipidworld.com/content/7/1/27</link>
			
			 	<dc:creator>Mehdi Nematbakhsh, Shaghayegh Haghjooyjavanmard, Farzaneh Mahmoodi and Ali-Reza Monajemi</dc:creator>
			
			<dc:source>Lipids in Health and Disease 2008, 7:27</dc:source>
			<dc:date>2008-08-02</dc:date>
			<dc:identifier>doi:10.1186/1476-511X-7-27</dc:identifier>
			
			
							
					<prism:publicationName>Lipids in Health and Disease</prism:publicationName>
					
			
							
					<prism:issn>1476-511X</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>27</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-02</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.lipidworld.com/content/7/1/26">
            
            <title>Weight loss and brown adipose tissue reduction in rat model of sleep apnea</title>
			<description>Background -Obesity is related to obstructive sleep apnea-hypopnea syndrome (OSAHS), but its roles in OSAHS as cause or consequence are not fully clarified. Isocapnic intermittent hypoxia (IIH) is a model of OSAHS. We verified the effect of IIH on body weight and brown adipose tissue (BAT) of Wistar rats.
Methods:
Nine-month-old male breeders Wistar rats of two groups were studied: 8 rats submitted to IIH and 5 control rats submitted to sham IIH. The rats were weighed at the baseline and at the end of three weeks, after being placed in the IIH apparatus seven days per week, eight hours a day, in the lights on period, simulating an apnea index of 30/hour. After experimental period, the animals were weighed and measured as well as the BAT, abdominal, perirenal, and epididymal fat, the heart, and the gastrocnemius muscle.
Results:
Body weight of the hypoxia group decreased 17 &#177; 7 grams, significantly different from the variation observed in the control group (p = 0,001). The BAT was 15% lighter in the hypoxia group and reached marginally the alpha error probability (p = 0.054).
Conclusion:
Our preliminary results justify a larger study for a longer time in order to confirm the effect of isocapnic intermittent hypoxia on body weight and BAT.</description>
			<link>http://www.lipidworld.com/content/7/1/26</link>
			
			 	<dc:creator>Denis Martinez, Luiz FT Vasconcellos, Patricia G de Oliveira and Signor&#225; P Konrad</dc:creator>
			
			<dc:source>Lipids in Health and Disease 2008, 7:26</dc:source>
			<dc:date>2008-07-31</dc:date>
			<dc:identifier>doi:10.1186/1476-511X-7-26</dc:identifier>
			
			
							
					<prism:publicationName>Lipids in Health and Disease</prism:publicationName>
					
			
							
					<prism:issn>1476-511X</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>26</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-31</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.lipidworld.com/content/7/1/25">
            
            <title>Increased plasma apoM levels in the patients suffered from hepatocellular carcinoma and other chronic liver diseases</title>
			<description>ObjectiveTo determine plasma apolipoprotein M (apoM) levels and other lipid profiles in hepatocellular carcinoma (HCC) patients compared to other chronic liver diseases and normal subjects.Materials and methods36 HCC, 68 chronic hepatitis, 29 liver cirrhosis patients and 64 normal controls were subjected in the present study. Serum lipids, lipoproteins, apolipoprotein AI (apoAI) and apoB were determined by the conventional methods. Plasma apoM levels were semi-quantitatively determined by both dot-blotting and western blotting analysis.
Results:
Serum levels of triglycerides (TG), HDL-cholesterol, apoAI and lipoprotein (a) (Lp(a)) were significantly lower in the HCC patients than in the normal subjects, whereas there were no obvious differences on serum total cholesterol, LDL-cholesterol and apoB between HCC patients and normal subjects. However, plasma apoM levels in HCC patients were significantly increased than those in the normal subjects, but lower than those in the chronic hepatitis and cirrhosis patients.
Conclusion:
It is concluded that serum TG, apoAI, HDL-C and Lp(a) were significantly decreased in HCC patients than in controls, whereas plasma apoM levels were significantly increased in the HCC patients. Decreased serum TG, apoAI, HDL-C and Lp(a) may reflect the liver damage in HCC patients, whereas the clinical significance of increased plasma apoM levels in relation to HCC is not clear.</description>
			<link>http://www.lipidworld.com/content/7/1/25</link>
			
			 	<dc:creator>Jingting Jiang, Xiaoying Zhang, Changping Wu, Xihu Qin, Guanghua Luo, Haifeng Deng, Minyang Lu, Bin Xu, Min Li, Mei Ji and Ning Xu</dc:creator>
			
			<dc:source>Lipids in Health and Disease 2008, 7:25</dc:source>
			<dc:date>2008-07-24</dc:date>
			<dc:identifier>doi:10.1186/1476-511X-7-25</dc:identifier>
			
			
							
					<prism:publicationName>Lipids in Health and Disease</prism:publicationName>
					
			
							
					<prism:issn>1476-511X</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>25</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-24</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.lipidworld.com/content/7/1/24">
            
            <title>The omega-3 fatty acid, eicosapentaenoic acid (EPA), prevents the damaging effects of tumour necrosis factor (TNF)-alpha during murine skeletal muscle cell differentiation</title>
			<description>Background:
Eicosapentaenoic acid (EPA) is a &#974;-3 polyunsaturated fatty acid with anti-inflammatory and anti-cachetic properties that may have potential benefits with regards to skeletal muscle atrophy conditions where inflammation is present. It is also reported that pathologic levels of the pro-inflammatory cytokine tumour necrosis factor (TNF)-&#945; are associated with muscle wasting, exerted through inhibition of myogenic differentiation and enhanced apoptosis. These findings led us to hypothesize that EPA may have a protective effect against skeletal muscle damage induced by the actions of TNF-&#945;.
Results:
The deleterious effects of TNF-&#945; on C2C12 myogenesis were completely inhibited by co-treatment with EPA. Thus, EPA prevented the TNF-mediated loss of MyHC expression and significantly increased myogenic fusion (p &lt; 0.05) and myotube diameter (p &lt; 0.05) indices back to control levels. EPA protective activity was associated with blocking cell death pathways as EPA completely attenuated TNF-mediated increases in caspase-8 activity (p &lt; 0.05) and cellular necrosis (p &lt; 0.05) back to their respective control levels. EPA alone significantly reduced spontaneous apoptosis and necrosis of differentiating myotubes (p &lt; 0.001 and p &lt; 0.05, respectively). A 2 hour pre-treatment with EPA, prior to treatment with TNF alone, gave similar results.
Conclusion:
In conclusion, EPA has a protective action against the damaging effects of TNF-&#945; on C2C12 myogenesis. These findings support further investigations of EPA as a potential therapeutic agent during skeletal muscle regeneration following injury.</description>
			<link>http://www.lipidworld.com/content/7/1/24</link>
			
			 	<dc:creator>Peter Magee, Stephen Pearson and Jeremy Allen</dc:creator>
			
			<dc:source>Lipids in Health and Disease 2008, 7:24</dc:source>
			<dc:date>2008-07-18</dc:date>
			<dc:identifier>doi:10.1186/1476-511X-7-24</dc:identifier>
			
			
							
					<prism:publicationName>Lipids in Health and Disease</prism:publicationName>
					
			
							
					<prism:issn>1476-511X</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>24</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-18</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.lipidworld.com/content/7/1/23">
            
            <title>Lipoprotein binding preference of CD36 is altered by filipin treatment</title>
			<description>The class B scavenger receptor CD36 binds multiple ligands, including oxidized and native lipoprotein species. CD36 and the related receptor SR-B1 have been localized to caveolae, domains that participate in cell signaling, transcytosis, and regulation of cellular cholesterol homeostasis. Previous work has indicated that the ligand preference of CD36 may depend on the cell type in which it is expressed. To determine if the presence or absence of caveolae is the determining factor for lipoprotein preference, we treated CHO-CD36 and C32 cells with filipin. Filipin treatment rapidly increased the binding capacity of CD36 for the native lipoproteins HDL and LDL, but did not affect the binding capacity of CD36 for oxidized LDL. Filipin treatment affected the distribution of caveolin and CD36 suggesting that the presence caveolae may modulate the ligand preference of CD36. However, its molecular mechanism how CD36 and caveolin interaction in regulating lipoprotein transport remains to be further studied.</description>
			<link>http://www.lipidworld.com/content/7/1/23</link>
			
			 	<dc:creator>Jianshe Zhang, Wuying Chu and Ian Crandall</dc:creator>
			
			<dc:source>Lipids in Health and Disease 2008, 7:23</dc:source>
			<dc:date>2008-06-26</dc:date>
			<dc:identifier>doi:10.1186/1476-511X-7-23</dc:identifier>
			
			
							
					<prism:publicationName>Lipids in Health and Disease</prism:publicationName>
					
			
							
					<prism:issn>1476-511X</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>23</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-26</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.lipidworld.com/content/7/1/22">
            
            <title>Plasma PCSK9 levels are significantly modified by statins and fibrates in humans</title>
			<description>Background:
Proprotein convertase subtilisin kexin-like 9 (PCSK9) is a secreted glycoprotein that is transcriptionally regulated by cholesterol status. It modulates levels of circulating low density lipoprotein cholesterol (LDLC) by negatively regulating low density lipoprotein receptor (LDLR) levels. PCSK9 variants that result in 'gain of function' have been linked to autosomal dominant hypercholesterolemia, while significant protection from coronary artery disease has been documented in individuals who carry 'loss of function' PCSK9 variants. PCSK9 circulates in human plasma, and we previously reported that plasma PCSK9 is positively correlated with total cholesterol and LDLC in men.
Results:
Herein, we report the effects of two lipid-modulating therapies, namely statins and fibrates, on PCSK9 plasma levels in human subjects. We also document their effects on endogenous PCSK9 and LDLR expression in a human hepatocyte cell line, HepG2, using immunoprecipitation and immunoblot analyses. Changes in plasma PCSK9 following fenofibrate or gemfibrozil treatments (fibric acid derivatives) were inversely correlated with changes in LDLC levels (r = -0.558, p = 0.013). Atorvastatin administration (HMGCoA reductase inhibitor) significantly increased plasma PCSK9 (7.40%, p = 0.033) and these changes were inversely correlated with changes in LDLC levels (r = -0.393, p = 0.012). Immunoblot analyses of endogenous PCSK9 and LDLR expression by HepG2 cells in response to statins and fibrates showed that LDLR is more upregulated than PCSK9 by simvastatin (2.6&#215; vs 1.5&#215;, respectively at 10 &#956;M), while fenofibrate did not induce changes in either.
Conclusion:
These results suggest that in vivo (1) statins directly increase PCSK9 expression while (2) fibrates affect PCSK9 expression indirectly through its modulation of cholesterol levels and (3) that these therapies could be improved by combination with a PCSK9 inhibitor, constituting a novel hypercholesterolemic therapy, since PCSK9 was significantly upregulated by both treatments.</description>
			<link>http://www.lipidworld.com/content/7/1/22</link>
			
			 	<dc:creator>Janice Mayne, Thilina Dewpura, Angela Raymond, Marion Cousins, Anna Chaplin, Karen A Lahey, Stephen A LaHaye, Majambu Mbikay, Teik Chye Ooi and Michel Chr&#233;tien</dc:creator>
			
			<dc:source>Lipids in Health and Disease 2008, 7:22</dc:source>
			<dc:date>2008-06-11</dc:date>
			<dc:identifier>doi:10.1186/1476-511X-7-22</dc:identifier>
			
			
							
					<prism:publicationName>Lipids in Health and Disease</prism:publicationName>
					
			
							
					<prism:issn>1476-511X</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>22</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-11</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.lipidworld.com/content/7/1/21">
            
            <title>Effect of dietary fat on hepatic liver X receptor expression in P-glycoprotein deficient mice: implications for cholesterol metabolism</title>
			<description>Pgp (P-glycoprotein, MDR1, ABCB1) is an energy-dependent drug efflux pump that is a member of the ATP-binding cassette (ABC) family of proteins. Preliminary studies have reported that nonspecific inhibitors of Pgp affect synthesis and esterification of cholesterol, putatively by blocking trafficking of cholesterol from the plasma membrane to the endoplasmic reticulum, and that relative increases in Pgp within a given cell type are associated with increased accumulation of cholesterol. Several key efflux proteins involved in the cholesterol metabolic pathway are transcriptionally regulated by the nuclear hormone liver X receptor (LXR). Therefore, to examine the interplay between P-glycoprotein and the cholesterol metabolic pathway, we utilized a high fat, normal cholesterol diet to upregulate LXR&#945; without affecting dietary cholesterol. Our research has demonstrated that mice lacking in P-glycoprotein do not exhibit alterations in hepatic total cholesterol storage, circulating plasma total cholesterol levels, or total cholesterol concentration in the bile when compared to control animals on either a normal (25% calories from dietary fat) or high fat (45% calories from dietary fat) diet. However, p-glycoprotein deficient mice (Mdr1a-/-/1b-/-) exhibit increased hepatic LXR&#945; protein expression and an elevation in fecal cholesterol concentration when compared to controls.</description>
			<link>http://www.lipidworld.com/content/7/1/21</link>
			
			 	<dc:creator>Sheila J Thornton, Evelyn Wong, Stephen D Lee and Kishor M Wasan</dc:creator>
			
			<dc:source>Lipids in Health and Disease 2008, 7:21</dc:source>
			<dc:date>2008-06-11</dc:date>
			<dc:identifier>doi:10.1186/1476-511X-7-21</dc:identifier>
			
			
							
					<prism:publicationName>Lipids in Health and Disease</prism:publicationName>
					
			
							
					<prism:issn>1476-511X</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>21</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-11</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.lipidworld.com/content/7/1/20">
            
            <title>The effects of beta2 adrenergic receptor gene polymorphism in lipid profiles</title>
			<description>Background:
Explore the interaction between apolipoprotein E (Apo E), phospholipase A2 (PLA2) and &#946;2 adrenergic receptor (&#946;2-AR) gene polymorphisms and lipid profiles in an elderly Chinese population.
Methods:
Five hundred subjects aged 65 to 74 years were randomly selected from a community in southern Taiwan to assess the relationship between Apo E, PLA2 and &#946;2-AR gene polymorphisms and lipid profiles. Two hundred sixty-seven participants agreed to have venous blood drawn for DNA studies.
Results:
Two statistically significant differences were noted in TC and LDL-C in the Gln27Glu of the &#946;2-AR gene polymorphism (P = 0.007, P = 0.022). The low-income group had a higher HDL-C level (p = 0.076). The Gln27Glu polymorphism Glu/Glu or Gln/Glu subjects had lower TC levels compared to the Gln27Glu polymorphism Gln/Gln subjects (p = 0.092).     Lower TC levels (p = 0.082) and lower LDL-C levels (p = 0.045) in subjects with the Cys19Arg16Glu27 haplotype. Lower TC levels (p = 0.06) were also noted in subjects with the Cys19Gly 16Glu27 haplotype. On the other hand, higher VLDL-C levels (p = 0.185) and higher triglyceride (TG) levels (p = 0.190) were noted in subjects with the Cys19Gly 16Gln27 haplotype. The &#949;2 allele combined with low income had a positive effect on HDL-C (p = 0.0011), after adding the income factor in this study.
Conclusion:
When the effects of Apo E and PLA2 on lipid profiles were included in this study, &#946;2-AR gene polymorphisms reduced significant effect on lipid profiles. Similarly, low income increased effect on HDL-C. This study appeared that the results of gene-gene and gene-environment interaction, it should be considered in further studies for lipid profiles.</description>
			<link>http://www.lipidworld.com/content/7/1/20</link>
			
			 	<dc:creator>Wei-Tsung Kao, Yung-Chieh Yen and For-Wey Lung</dc:creator>
			
			<dc:source>Lipids in Health and Disease 2008, 7:20</dc:source>
			<dc:date>2008-05-21</dc:date>
			<dc:identifier>doi:10.1186/1476-511X-7-20</dc:identifier>
			
			
							
					<prism:publicationName>Lipids in Health and Disease</prism:publicationName>
					
			
							
					<prism:issn>1476-511X</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>20</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-21</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
    <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
